Yukinari Kato

Summary

Country: Japan

Publications

  1. ncbi Induction of podoplanin by transforming growth factor-beta in human fibrosarcoma
    Hiroyuki Suzuki
    Department of Experimental Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
    FEBS Lett 582:341-5. 2008
  2. ncbi Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker verification
    Atsushi Kuno
    Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Central 2, 1 1 1, Umezono, Ibaraki 305 8568, Japan
    Mol Cell Proteomics 8:99-108. 2009
  3. ncbi Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation
    Yukinari Kato
    Regional Innovation Strategy Support Program, Tohoku University Graduate School of Medicine, 2 1 Seiryo machi, Aoba ku, Sendai, Miyagi 980 8575, Japan Electronic address
    Biochem Biophys Res Commun 433:374-8. 2013
  4. ncbi A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation
    Yukinari Kato
    Regional Innovation Strategy Support Program, Tohoku University Graduate School of Medicine, 2 1 Seiryo machi, Sendai, Miyagi 980 8575, Japan
    Biochem Biophys Res Commun 432:564-7. 2013
  5. ncbi Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas
    Yukinari Kato
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Nucl Med Biol 37:785-94. 2010
  6. ncbi A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation
    Yukinari Kato
    Department of Pathology, Duke University Medical Center, DUMC 3156, Durham, NC 27710, USA
    Biochem Biophys Res Commun 390:547-51. 2009
  7. ncbi Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain
    Yukinari Kato
    Research Center for Glycoscience, National Institute of Advanced Industrial Science and Technology, Open Space Laboratory C 2, 1 1 1 Umezono, Tsukuba, Ibaraki 305 8568, Japan
    Biochem Biophys Res Commun 349:1301-7. 2006
  8. ncbi Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2
    Yukinari Kato
    Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Open Space Laboratory C 2, 1 1 1 Umezono, Tsukuba, Ibaraki 305 8568, Japan
    Cancer Sci 99:54-61. 2008
  9. ncbi Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity
    Mika Kato Kaneko
    Molecular Tumor Marker Research Team, Global COE Program, Yamagata University Faculty of Medicine, Yamagata, Japan
    Cancer Sci 103:1913-9. 2012
  10. ncbi Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor
    Mika Kato Kaneko
    Department of Experimental and Forensic Pathology, Yamagata University School of Medicine, 2 2 2, Iida Nishi, Yamagata 990 9585, Japan
    Gene 378:52-7. 2006

Detail Information

Publications32

  1. ncbi Induction of podoplanin by transforming growth factor-beta in human fibrosarcoma
    Hiroyuki Suzuki
    Department of Experimental Pathology, Graduate School of Comprehensive Human Sciences, University of Tsukuba, Ibaraki, Japan
    FEBS Lett 582:341-5. 2008
    ..TGF-beta type I receptor inhibitor (SB431542) and short hairpin RNAs for Smad4 inhibited the podoplanin induction by TGF-beta. These results suggest that TGF-beta is a physiological regulator of podoplanin in tumor cells...
  2. ncbi Focused differential glycan analysis with the platform antibody-assisted lectin profiling for glycan-related biomarker verification
    Atsushi Kuno
    Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Central 2, 1 1 1, Umezono, Ibaraki 305 8568, Japan
    Mol Cell Proteomics 8:99-108. 2009
    ..Thus, the established system should provide a powerful pipeline in support of on-going efforts in glyco-biomarker discovery...
  3. ncbi Generation of a novel monoclonal antibody WMab-1 specific for IDH2-R172W mutation
    Yukinari Kato
    Regional Innovation Strategy Support Program, Tohoku University Graduate School of Medicine, 2 1 Seiryo machi, Aoba ku, Sendai, Miyagi 980 8575, Japan Electronic address
    Biochem Biophys Res Commun 433:374-8. 2013
    ..WMab-1 also specifically stained the IDH2-R172W-expressing glioma cells in immunohistochemistry. This is the first report to establish an anti-IDH2-R172W-specific mAb, which could be useful in the diagnosis of IDH2-R172W-bearing tumors...
  4. ncbi A novel monoclonal antibody GMab-m1 specifically recognizes IDH1-R132G mutation
    Yukinari Kato
    Regional Innovation Strategy Support Program, Tohoku University Graduate School of Medicine, 2 1 Seiryo machi, Sendai, Miyagi 980 8575, Japan
    Biochem Biophys Res Commun 432:564-7. 2013
    ..This is the first report to establish anti-IDH1-R132G-specific mAbs, which is useful in immunohistochemistry of IDH1-R132G-bearing tumors...
  5. ncbi Evaluation of anti-podoplanin rat monoclonal antibody NZ-1 for targeting malignant gliomas
    Yukinari Kato
    Department of Pathology, Duke University Medical Center, Durham, NC 27710, USA
    Nucl Med Biol 37:785-94. 2010
    ..The purpose of this study was to determine whether an anti-podoplanin antibody is suitable to target radionuclides to malignant gliomas...
  6. ncbi A monoclonal antibody IMab-1 specifically recognizes IDH1R132H, the most common glioma-derived mutation
    Yukinari Kato
    Department of Pathology, Duke University Medical Center, DUMC 3156, Durham, NC 27710, USA
    Biochem Biophys Res Commun 390:547-51. 2009
    ..In conclusion, we established an anti-IDH1(R132H)-specific monoclonal antibody IMab-1, which should be significantly useful for diagnosis and biological evaluation of mutation-bearing gliomas...
  7. ncbi Inhibition of tumor cell-induced platelet aggregation using a novel anti-podoplanin antibody reacting with its platelet-aggregation-stimulating domain
    Yukinari Kato
    Research Center for Glycoscience, National Institute of Advanced Industrial Science and Technology, Open Space Laboratory C 2, 1 1 1 Umezono, Tsukuba, Ibaraki 305 8568, Japan
    Biochem Biophys Res Commun 349:1301-7. 2006
    ..We infer that NZ-1 is useful to determine whether platelet aggregation is podoplanin-specific or not. Furthermore, podoplanin might become a therapeutic target of glioblastoma for antibody-based therapy...
  8. ncbi Molecular analysis of the pathophysiological binding of the platelet aggregation-inducing factor podoplanin to the C-type lectin-like receptor CLEC-2
    Yukinari Kato
    Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, Open Space Laboratory C 2, 1 1 1 Umezono, Tsukuba, Ibaraki 305 8568, Japan
    Cancer Sci 99:54-61. 2008
    ..Podoplanin and CLEC-2 might represent promising therapeutic targets in cancer metastasis...
  9. ncbi Chimeric anti-podoplanin antibody suppresses tumor metastasis through neutralization and antibody-dependent cellular cytotoxicity
    Mika Kato Kaneko
    Molecular Tumor Marker Research Team, Global COE Program, Yamagata University Faculty of Medicine, Yamagata, Japan
    Cancer Sci 103:1913-9. 2012
    ..Targeting therapy to podoplanin-expressing tumors should be useful as a novel immunotherapy...
  10. ncbi Conservation of a platelet activating domain of Aggrus/podoplanin as a platelet aggregation-inducing factor
    Mika Kato Kaneko
    Department of Experimental and Forensic Pathology, Yamagata University School of Medicine, 2 2 2, Iida Nishi, Yamagata 990 9585, Japan
    Gene 378:52-7. 2006
    ..In conclusion, we provide evidence that Aggrus homologues conserved the segment of EDxxVTPG in their extracellular domain which are critical for their platelet aggregation-inducing activities...
  11. ncbi Immunohistochemical detection of IDH1 mutation, p53, and internexin as prognostic factors of glial tumors
    Shingo Takano
    Department of Neurological Surgery, Institute of Clinical Medicine, University of Tsukuba, 1 1 1 Tennoudai, 305 8575, Ibaraki, Tsukuba, Japan
    J Neurooncol 108:361-73. 2012
    ....
  12. ncbi Recombinant anti-podoplanin (NZ-1) immunotoxin for the treatment of malignant brain tumors
    Vidyalakshmi Chandramohan
    Preston Robert Tisch Brain Tumor Center at Duke and Department of Pathology, Duke University Medical Center, Durham, NC
    Int J Cancer 132:2339-48. 2013
    ..001). In preclinical studies, NZ-1-(scdsFv)-PE38KDEL exhibited significant potential as a targeting agent for malignant brain tumors...
  13. ncbi Functional glycosylation of human podoplanin: glycan structure of platelet aggregation-inducing factor
    Mika Kato Kaneko
    Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology, C 2, 1 1 1 Umezono, Tsukuba, Ibaraki 305 8568, Japan
    FEBS Lett 581:331-6. 2007
    ..Sialic acid-deficient podoplanin recovered its activity after additional sialylation. These results indicated that the sialylated Corel at Thr52 is critical for podoplanin-induced platelet aggregation...
  14. ncbi Engineering of mucin-type human glycoproteins in yeast cells
    Koh Amano
    Research Center for Medical Glycoscience and Research Institute for Cell Engineering, National Institute of Advanced Industrial Science and Technology, 1 1 1 Higashi, Tsukuba 305 8566, Japan
    Proc Natl Acad Sci U S A 105:3232-7. 2008
    ..The yeast system we describe here is able to produce glycoproteins modified at different glycosylation sites and has the potential for use in basic research and pharmaceutical applications...
  15. ncbi GMab-1, a high-affinity anti-3'-isoLM1/3',6'-isoLD1 IgG monoclonal antibody, raised in lacto-series ganglioside-defective knockout mice
    Yukinari Kato
    Department of Pathology, Duke University Medical Center, DUMC 3156, Durham, NC 27710, USA
    Biochem Biophys Res Commun 391:750-5. 2010
    ....
  16. ncbi Functional sialylated O-glycan to platelet aggregation on Aggrus (T1alpha/Podoplanin) molecules expressed in Chinese hamster ovary cells
    Mika Kaneko
    Department of Experimental and Forensic Pathology, Yamagata University School of Medicine, 2 2 2, Iida Nishi, Yamagata 990 9585, Japan
    J Biol Chem 279:38838-43. 2004
    ..This oligosaccharide structure is known as tumor-associated antigen, which is potentially related to the metastasis process of cancer cells...
  17. ncbi Increased expression of highly sulfated keratan sulfate synthesized in malignant astrocytic tumors
    Yukinari Kato
    Research Center for Medical Glycoscience RCMG, National Institute of Advanced Industrial Science and Technology AIST, Open Space Laboratory C 2, 1 1 1, Tsukuba, Ibaraki 305 8568, Japan
    Biochem Biophys Res Commun 369:1041-6. 2008
    ..In immunohistochemistry, KS is highly expressed in cell surface of malignant astrocytic tumors. Taken together, KS might be associated with the malignancy of astrocytic tumors, and be useful for a prognostic factor of astrocytic tumors...
  18. ncbi Expression of highly sulfated keratan sulfate synthesized in human glioblastoma cells
    Norihito Hayatsu
    Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology AIST, Tsukuba, Ibaraki 305 8568, Japan
    Biochem Biophys Res Commun 368:217-22. 2008
    ..Taken together, these results suggest that LN229 produces 5D4-reactive highly sulfated KS and is useful to investigate the KS structure and function in glioblastoma...
  19. ncbi Detection of IDH1 mutation in human gliomas: comparison of immunohistochemistry and sequencing
    Shingo Takano
    Department of Neurosurgery, Institute of Clinical Medicine, University of Tsukuba, 1 1 1 Tennoudai, Tsukuba, Ibaraki 305 8575, Japan
    Brain Tumor Pathol 28:115-23. 2011
    ..Therefore, IMab-1 is likely to be useful for the diagnosis of mutation-bearing gliomas and for determining the treatment strategy of grade III gliomas...
  20. ncbi Establishment of novel monoclonal antibodies KMab-1 and MMab-1 specific for IDH2 mutations
    Mika Kato Kaneko
    Regional Innovation Strategy Support Program, Tohoku University Graduate School of Medicine, 2 1 Seiryo machi, Aoba ku, Sendai, Miyagi 980 8575, Japan
    Biochem Biophys Res Commun 432:40-5. 2013
    ..In immunohistochemical analysis, MMab-1 specifically stained IDH2-R172M-expressing glioma. This is the first report to establish anti-IDH2-mutation-specific mAbs, which could be useful in diagnosis of mutation-bearing tumors...
  21. ncbi Establishment of a novel monoclonal antibody SMab-1 specific for IDH1-R132S mutation
    Mika Kato Kaneko
    Molecular Tumor Marker Research Team, The Oncology Research Center, Advanced Molecular Epidemiology Research Institute, Yamagata University Faculty of Medicine, 2 2 2 Iida nishi, Yamagata 990 9585, Japan
    Biochem Biophys Res Commun 406:608-13. 2011
    ..We newly established an anti-IDH1-R132S-specific mAb SMab-1 for use in diagnosis of mutation-bearing gliomas...
  22. ncbi Deletion polymorphism of SIGLEC14 and its functional implications
    Masahiro Yamanaka
    Research Center for Medical Glycoscience, National Institute of Advanced Industrial Science and Technology AIST, Tsukuba, Ibaraki, Japan
    Glycobiology 19:841-6. 2009
    ..The forced expression of Siglec-14 in a monocytic cell line-enhanced TNF-alpha secretion elicited by lipopolysaccharide. These results imply that Siglec-14 may play some role in bacterial infection...
  23. ncbi Molecular characterization of a human monoclonal antibody to B antigen in ABO blood type
    Mika Kaneko
    Department of Forensic Medicine, Yamagata University School of Medicine, 2 2 2 Iida nishi, Yamagata 990 9585, Japan
    Immunol Lett 86:45-51. 2003
    ..We think that this method is suitable for cDNA preparation of human monoclonal antibodies to blood group antigens and for sequence analysis...
  24. ncbi Tetraspanin family member CD9 inhibits Aggrus/podoplanin-induced platelet aggregation and suppresses pulmonary metastasis
    Youya Nakazawa
    Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, Tokyo
    Blood 112:1730-9. 2008
    ..Therefore, CD9 may act as a metastasis suppressor, at least in part, by neutralizing Aggrus-mediated platelet aggregation...
  25. ncbi Molecular identification of Aggrus/T1alpha as a platelet aggregation-inducing factor expressed in colorectal tumors
    Yukinari Kato
    Institute of Molecular and Cellular Biosciences, The University of Tokyo, Bunkyo ku, Tokyo 113 0032, Japan
    J Biol Chem 278:51599-605. 2003
    ..These results suggest that Aggrus/T1alpha is a newly identified, platelet aggregation-inducing factor expressed in colorectal tumors...
  26. ncbi Involvement of the snake toxin receptor CLEC-2, in podoplanin-mediated platelet activation, by cancer cells
    Katsue Suzuki-Inoue
    Department of Clinical and Laboratory Medicine, Faculty of Medicine, University of Yamanashi, 1110 Shimokato, Chuo, Yamanashi, 409 3898, Japan
    J Biol Chem 282:25993-6001. 2007
    ..These findings suggest that CLEC-2 is a physiological target protein of podoplanin and imply that it is involved in podoplanin-induced platelet aggregation, tumor metastasis, and other cellular responses related to podoplanin...
  27. ncbi Aggrus: a diagnostic marker that distinguishes seminoma from embryonal carcinoma in testicular germ cell tumors
    Yukinari Kato
    Institute of Molecular and Cellular Biosciences, The University of Tokyo, 1-1-1, Yayoi, Bunkyo-ku, Tokyo 113-0032, Japan
    Oncogene 23:8552-6. 2004
    ..Specific markers for seminomas have not been reported, and Aggrus is a potential diagnostic marker for seminomas and may be associated with malignancies of the testis...
  28. ncbi Enhanced expression of Aggrus (T1alpha/podoplanin), a platelet-aggregation-inducing factor in lung squamous cell carcinoma
    Yukinari Kato
    Department of Experimental and Forensic Pathology, Yamagata University School of Medicine, Yamagata, Japan
    Tumour Biol 26:195-200. 2005
    ..These findings indicated that overexpression of Aggrus occurred in squamous cell carcinoma of the lung. Therefore, Aggrus could be a useful diagnostic marker for squamous cell carcinoma of the lung...
  29. ncbi Increased expression of podoplanin in malignant astrocytic tumors as a novel molecular marker of malignant progression
    Kazuhiko Mishima
    Department of Neurosurgery, Saitama Medical School, Saitama, 350 0495, Japan
    Acta Neuropathol 111:483-8. 2006
    ..Podoplanin mRNA and protein expression were markedly higher in glioblastomas than in anaplastic astrocytomas. These data suggest that podoplanin expression might be associated with malignancy of astrocytic tumors...
  30. ncbi Podoplanin expression in primary central nervous system germ cell tumors: a useful histological marker for the diagnosis of germinoma
    Kazuhiko Mishima
    Department of Neurosurgery, Saitama Medical School, 38 Morohongo, Moroyama machi, Iruma gun, 350 0495, Saitama, Japan
    Acta Neuropathol 111:563-8. 2006
    ..Thus, podoplanin expression may be a sensitive immunohistochemical marker for germinoma in CNS GCTs. As such, it may be useful for diagnosis, for monitoring the efficacy of treatment, and as a potential target for antibody-based therapy...
  31. ncbi The platelet aggregation-inducing factor aggrus/podoplanin promotes pulmonary metastasis
    Akiko Kunita
    Cancer Chemotherapy Center, Japanese Foundation for Cancer Research, 3 10 6, Ariake, Koto ku, Tokyo 135 8550, Japan
    Am J Pathol 170:1337-47. 2007
    ..Thus, Aggrus could serve as an ideal therapeutic target for drug development to block metastasis...
  32. ncbi Neutralization of blood group A-antigen by a novel anti-A antibody: overcoming ABO-incompatible solid-organ transplantation
    Yasushi Hasegawa
    Department of Surgery, Keio University School of Medicine, Tokyo, Japan
    Transplantation 85:378-85. 2008
    ..Various strategies to reduce antiblood group antibody by overcoming ABO-incompatible transplantation have been tried. However, antigen-suppressing procedures have not been performed...